查詢結果分析
相關文獻
- Preoperative Serum C-reactive Protein and Gastric Cancer; Clinical-pathological Correlation and Prognostic Significance
- C-reactive Protein and Malignancy: Clinico-pathological Association and Therapeutic Implication
- Intraluminal Mucin Pool in Mucinous Gastric Adenocarcinoma: A Case Report
- Prognostic Factors in Node-Negative Breast Cancer Patients: The Experience in Taiwan
- 胃癌之流行病學特徵及危險因子
- Postoperative Radiotherapy of Adult Supratentorial High-grade Astrocytoma
- Dispute of Extended Lymph Node Dissection for Gastric Cancer
- 源自胃癌的克魯根堡氏瘤:十年臨床經瞼
- 胃癌化學治療之進展
- Pregnancy Associated with Gastric Carcinoma
頁籤選單縮合
題 名 | Preoperative Serum C-reactive Protein and Gastric Cancer; Clinical-pathological Correlation and Prognostic Significance=C-反應性蛋白質在胃癌病人之臨床病理關聯和預後影響 |
---|---|
作 者 | 張承志; 孫建峰; 白鴻嘉; 王文科; 謝清川; 郭亮鉾; 王嘉修; | 書刊名 | 長庚醫誌 |
卷 期 | 33:3 2010.05-06[民99.05-06] |
頁 次 | 頁301-312 |
分類號 | 414.81 |
關鍵詞 | C-反應性蛋白質; 發炎性生物標記; 預後因子; 胃癌; C-reactive protein; Inflammatory biomarker; Prognostic factor; Gastric cancer; |
語 文 | 英文(English) |
中文摘要 | C- (CRP) CRP CRP 170 112 58 65.1 ( 29-89 ) 405 CRP 405 95 (CRP = 3.0 mg/L) 170 65 (38.2%) CRP (p < 0.001) (p = 0.009) (p = 0.001) (≥ 5 cm) (p < 0.001) (p = 0.001) (p < 0.001) (p = 0.017) (p = 0.002) CRP (p = 0.001) CRP (≥ 3.0 mg/L) (< 3.0 mg/L) (27.1% 54.1% log rank p = 0.0010) 38.2% CRP |
英文摘要 | Background: C-reactive protein (CRP) is a widely-used systemic biomarker for inflammation. Serum CRP is elevated in many malignancies, and is also a prognostic indicator of malignant potential. However, the prognostic significance for survival from gastric cancer has not yet been clarified. We studied the clinical- pathologic association and prognostic significance of preoperative serum CRP in gastric cancer patients. Methods: A total of 170 gastric cancer patients were included in this study. The mean age of the patients was 65.1 years (range, 29-89), and 112 were men. All gastric cancer patients had undergone gastric resection. The serum CRP levels of patients before the operation along with those from 405 healthy controls were measured by a high sensitivity CRP test. Results: The 95th percentile value (= 3.0 mg/L) of the serum CRP data in 405 healthy controls was set as the upper cut-off value of the normal range. Abnormally high levels of serum CRP were observed in 65 (38.2%) of our 170 patients in contrast to only 20 (4.9%) of the 405 healthy controls (p < 0.001). Elevated CRP was associated with older age (p = 0.009), grossly infiltrative type (p = 0.001), larger tumors (p < 0.001), serosal invasion (p = 0.001), lymph node metastasis (p < 0.001), distant metastasis (p = 0.017), and lymphatic invasion (p = 0.002). Overall, a higher CRP level was strongly parallel to a pathologically more advanced stage (p = 0.001). The 5-yr survival rate of patients with an elevated (> 3.0 mg/L) CRP was significantly worse than those without (≤ 3.0 mg/L) (27.1% versus 54.1%, log rank p = 0.0010). Conclusion: The preoperative serum CRP level was abnormally elevated in 38.2% of gastric cancer patients. Elevated CRP was associated with progressive disease or an advanced stage, and a worse survival. Although serum CRP is not a specific biomarker for gastric cancer, it might be a potential prognostic biomarker and a promising therapeutic target for gastric cancer patients. |
本系統中英文摘要資訊取自各篇刊載內容。